RxDoctor Payments Data

Jonathan Cohen, MD

Gastroenterology · New York, NYNPI 1790709533

Payments from drug & device makers

$93,542in general payments, 2019–2025

Across 502 payments — averaging $186.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Latin America, Inc.$49K
  • Otsuka America Pharmaceutical, Inc.$15K
  • Olympus Corporation$8K
  • Ferring Pharmaceuticals Inc.$3K
  • Gilead$3K
  • Olympus Medical Systems Corporation$3K
  • plus $13K from 36 others

What the payments were for

  • Consulting fees$11,78313%
  • Speaking & faculty fees$56,37260%
  • Travel & lodging$14,91416%
  • Food & beverage$10,38411%
  • Education$900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$93,542 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$325,008
Medicare patients
499
Services billed
6,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$358,930
CreonLipase/Protease/Amylase17$61,303
XifaxanRifaximin12$31,261
Mesalamine43$25,432
LinzessLinaclotide18$20,208
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates137$8,177
Famotidine436$7,633
ClenpiqSod Picosulf/Mag Ox/Citric Ac27$4,566
SutabSod Sulf/Pot Chloride/Mag Sulf20$3,213
Pantoprazole Sodium148$2,806
Rabeprazole Sodium62$2,690
Ursodiol15$1,286
Esomeprazole Magnesium16$564
Omeprazole26$500
Colchicine12$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$574$358,93013 claims
AbbVieCreon, Linzess$2,047$81,51235 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$776$31,26112 claims
Ferring Pharmaceuticals Inc.Clenpiq$3,090$4,56627 claims
Braintree Laboratories, Inc.Sutab$1,834$3,21320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →